Jacobs Levy Equity Management Inc. Decreases Position in Vanda Pharmaceuticals Inc. $VNDA

Key Points

• Jacobs Levy Equity Management Inc. has reduced its stake in Vanda Pharmaceuticals by 41.7%, selling 196,433 shares and now holding approximately 0.47% of the company.
• Vanda Pharmaceuticals reported a Q2 earnings loss of ($0.46) per share, missing the consensus estimate by ($0.12), with revenues below expectations at $52.59 million.
• Analysts have mixed views on Vanda Pharmaceuticals, with Wall Street Zen downgrading the stock to a "strong sell," while HC Wainwright maintains a "buy" rating with a price target of $20.00.

Jacobs Levy Equity Management Inc. trimmed its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 41.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 274,293 shares of the biopharmaceutical company's stock after selling 196,433 shares during the period. Jacobs Levy Equity Management Inc. owned 0.47% of Vanda Pharmaceuticals worth $1,259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Vanda Pharmaceuticals by 34.3% in the 1st quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company's stock valued at $256,000 after acquiring an additional 14,232 shares during the period. MetLife Investment Management LLC increased its position in shares of Vanda Pharmaceuticals by 18.9% in the 1st quarter. MetLife Investment Management LLC now owns 32,816 shares of the biopharmaceutical company's stock valued at $151,000 after acquiring an additional 5,210 shares during the period. Stonepine Capital Management LLC increased its position in shares of Vanda Pharmaceuticals by 40.6% in the 1st quarter. Stonepine Capital Management LLC now owns 35,148 shares of the biopharmaceutical company's stock valued at $161,000 after acquiring an additional 10,148 shares during the period. Walleye Capital LLC acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at $170,000. Finally, Hsbc Holdings PLC increased its position in shares of Vanda Pharmaceuticals by 17.8% in the 1st quarter. Hsbc Holdings PLC now owns 56,594 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 8,545 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

VNDA has been the topic of several research reports. Wall Street Zen downgraded Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Strong Buy" and a consensus price target of $16.50.

Vanda Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:VNDA traded down $0.03 during trading on Wednesday, reaching $4.44. 35,224 shares of the company's stock traded hands, compared to its average volume of 546,880. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $5.55. The firm has a market cap of $262.06 million, a PE ratio of -3.92 and a beta of 0.74. The company has a 50-day simple moving average of $4.58 and a 200-day simple moving average of $4.53.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). The business had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.